BIOLINERX LTD-SPONS ADR (BLRX) Stock Price, Forecast & Analysis
USA - NASDAQ:BLRX - US09071M2052 - ADR
BLRX Key Statistics, Chart & Performance
The current stock price of BLRX is 3.3899 USD. In the past month the price decreased by -16.37%. In the past year, price decreased by -81.61%.
BLRX Latest News, Press Relases and Analysis
BLRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.05 | 384.79B | ||
| AMGN | AMGEN INC | 14.74 | 173.55B | ||
| GILD | GILEAD SCIENCES INC | 14.4 | 146.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.92 | 106.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.56 | 69.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 870.26 | 58.18B | ||
| INSM | INSMED INC | N/A | 39.52B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.25 | 22.70B | ||
| INCY | INCYTE CORP | 16.39 | 20.55B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.21 | 20.54B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.46 | 14.70B |
Related stock screener links
About BLRX
Company Profile
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Company Info
BIOLINERX LTD-SPONS ADR
Modi'in Technology Park, 2 HaMa'ayan Street
Modiin 7177871 IL
CEO: Philip A. Serlin
Employees: 28
Phone: 97286429100
BIOLINERX LTD-SPONS ADR / BLRX FAQ
Can you describe the business of BIOLINERX LTD-SPONS ADR?
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
What is the current price of BLRX stock?
The current stock price of BLRX is 3.3899 USD. The price increased by 3.67% in the last trading session.
Does BLRX stock pay dividends?
BLRX does not pay a dividend.
What is the ChartMill rating of BIOLINERX LTD-SPONS ADR stock?
BLRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in BIOLINERX LTD-SPONS ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLRX.
Can you provide the market cap for BIOLINERX LTD-SPONS ADR?
BIOLINERX LTD-SPONS ADR (BLRX) has a market capitalization of 12.61M USD. This makes BLRX a Nano Cap stock.
BLRX Technical Analysis
BLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BLRX. BLRX has a bad profitability rating. Also its financial health evaluation is rather negative.
BLRX Financial Highlights
Over the last trailing twelve months BLRX reported a non-GAAP Earnings per Share(EPS) of -4.27. The EPS increased by 77.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.08% | ||
| ROE | -38.97% | ||
| Debt/Equity | 0.38 |